IL158631A0 - 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders - Google Patents

4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders

Info

Publication number
IL158631A0
IL158631A0 IL15863102A IL15863102A IL158631A0 IL 158631 A0 IL158631 A0 IL 158631A0 IL 15863102 A IL15863102 A IL 15863102A IL 15863102 A IL15863102 A IL 15863102A IL 158631 A0 IL158631 A0 IL 158631A0
Authority
IL
Israel
Prior art keywords
piperazinyl
anxiety
pain
phenyl
methyl
Prior art date
Application number
IL15863102A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101772A external-priority patent/SE0101772D0/xx
Priority claimed from SE0103820A external-priority patent/SE0103820D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL158631A0 publication Critical patent/IL158631A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15863102A 2001-05-18 2002-05-16 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders IL158631A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101772A SE0101772D0 (sv) 2001-05-18 2001-05-18 Novel compounds
SE0103820A SE0103820D0 (sv) 2001-11-15 2001-11-15 Novel compounds
PCT/SE2002/000956 WO2002094794A1 (en) 2001-05-18 2002-05-16 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders

Publications (1)

Publication Number Publication Date
IL158631A0 true IL158631A0 (en) 2004-05-12

Family

ID=26655470

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15863102A IL158631A0 (en) 2001-05-18 2002-05-16 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158631A IL158631A (en) 2001-05-18 2003-10-27 4-(phenyl-piperazinyl-methyl) benzamide derivatives, process for their preparation, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of pain, anxiety or functional gastrointestinal disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158631A IL158631A (en) 2001-05-18 2003-10-27 4-(phenyl-piperazinyl-methyl) benzamide derivatives, process for their preparation, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of pain, anxiety or functional gastrointestinal disorders

Country Status (31)

Country Link
US (3) US7229994B2 (OSRAM)
EP (2) EP1395567B1 (OSRAM)
JP (2) JP4549024B2 (OSRAM)
KR (2) KR100915263B1 (OSRAM)
CN (1) CN1269805C (OSRAM)
AR (1) AR035974A1 (OSRAM)
AT (1) ATE420866T1 (OSRAM)
AU (1) AU2002305994B2 (OSRAM)
BG (1) BG108333A (OSRAM)
BR (1) BR0209678A (OSRAM)
CA (1) CA2446326C (OSRAM)
CO (1) CO5540309A2 (OSRAM)
CY (1) CY1108913T1 (OSRAM)
CZ (1) CZ20033092A3 (OSRAM)
DE (1) DE60230869D1 (OSRAM)
DK (1) DK1395567T3 (OSRAM)
EE (1) EE05243B1 (OSRAM)
ES (1) ES2319876T3 (OSRAM)
HU (1) HUP0401086A3 (OSRAM)
IL (2) IL158631A0 (OSRAM)
IS (1) IS2625B (OSRAM)
MX (1) MXPA03010445A (OSRAM)
MY (1) MY140070A (OSRAM)
NO (1) NO326632B1 (OSRAM)
NZ (2) NZ529401A (OSRAM)
PL (1) PL367142A1 (OSRAM)
PT (1) PT1395567E (OSRAM)
RU (1) RU2297412C2 (OSRAM)
SI (1) SI1395567T1 (OSRAM)
SK (1) SK287555B6 (OSRAM)
WO (1) WO2002094794A1 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230869D1 (de) 2001-05-18 2009-03-05 Astrazeneca Ab 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
WO2003037342A1 (en) 2001-10-29 2003-05-08 Ardent Pharmaceuticals, Inc. Method of treating depression with delta receptor agonist compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
BRPI0415165A (pt) 2003-10-01 2007-01-09 Adolor Corp composto heterocìclico espirocìclico, composição farmacêutica, método para ligar receptores opióides, métodos para prevenir ou tratar dor, disfunção gastrointestinal, um distúrbio do trato urogenital, um distúrbio imunomodulatório, um distúrbio inflamatório, um distúrbio de função respiratória, ansiedade, distúrbio do humor, um distúrbio relacionado a estresse, distúrbio do sistema nervoso simpático, tosse, e um distúrbio motor, método para tratar uma lesão traumática ao sistema nervoso central, métodos para prevenir ou tratar acidente vascular, arritmia cardìaca, glaucoma, e disfunção sexual, métodos para tratar uma condição selecionada do grupo consistindo de choque, edema cerebral, isquemia cerebral, déficit cerebral após cirurgia cardìaca (bypass) e enxerto, lupus eritematoso sistêmico, doença de hodgkin, doença de sjogren, epilepsia, e rejeição em transplantes de órgão e enxertos de pele, e para tratar dependência de substáncias, métodos para melhorar a sobrevivência de órgãos e células, e cardioproteção após infarto do miocárdio, métodos para reduzir a necessidade de anestesia, para produzir ou manter um estado anestésico, derivado radiomarcado de um composto, derivado isotopicamente marcado de um composto, composto e método de diagnóstico por imagem
HRP20120343T1 (hr) * 2004-08-02 2012-05-31 Astrazeneca Ab Derivati diarilmetil piperazina, njihovi pripravci i njihova uporaba
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
CN101128447A (zh) * 2005-02-28 2008-02-20 阿斯利康(瑞典)有限公司 二芳基甲基哌嗪衍生物，其制备及其用途
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
TWI410406B (zh) 2005-05-13 2013-10-01 Otsuka Pharma Co Ltd 吡咯烷化合物
WO2007018459A1 (en) * 2005-08-08 2007-02-15 Astrazeneca Ab Therapeutic agents
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
EP2024364A1 (en) * 2006-05-26 2009-02-18 Neuromed Pharmaceuticals, Ltd. Heterocyclic compounds as calcium channel blockers
AU2007294968A1 (en) 2006-09-12 2008-03-20 Adolor Corporation Use of N-containing spirocompounds for the enhancement of cognitive function
JP2011520956A (ja) * 2008-05-20 2011-07-21 アストラゼネカ・アクチエボラーグ 不安大うつ病性障害を処置する方法
PL2307389T3 (pl) 2008-06-20 2013-05-31 Astrazeneca Ab Pochodne dibenzotiazepiny i ich zastosowanie
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US10208016B2 (en) 2013-06-21 2019-02-19 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN104163788A (zh) * 2014-07-07 2014-11-26 湖南华腾制药有限公司 一种吡啶衍生物的制备方法
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
CN112245432B (zh) * 2020-11-05 2021-12-21 东南大学 一种1-二苯甲基-4-甲基哌嗪类化合物在制备抗抑郁症药物中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH583713A5 (OSRAM) 1973-06-29 1977-01-14 Cermol Sa
DE2900810A1 (de) 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
IT1140978B (it) 1980-05-23 1986-10-10 Selvi & C Spa 1-(4-clorobenzidril)-4-(2,3-diidros sipropil)-piperazina, metodi per la sua preparazione e relative composizione farmaceutiche
GB8320701D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IT1196150B (it) 1984-06-19 1988-11-10 Poli Ind Chimica Spa Derivati di 1-(bis-(4-fluorofenil)metil)-4-(3-fenil-2-propenil)-esaidro-1h-1,4-diazepina ad attivita' calcio antagonista,sua preparazione e composizioni che lo contengono
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4829065A (en) 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
US5840896A (en) * 1989-11-22 1998-11-24 Janssen Pharmaceutica, N.V. Method of preventing or limiting reperfusion damage
CA2044143C (en) 1989-11-22 2002-11-19 Herman Van Belle Method of preventing or limiting reperfusion damage
HUT65943A (en) 1990-08-29 1994-08-29 Upjohn Co Process for producing benzothiazolylmethyl- and pyperazinomethyl-2,4,6-cycloheptatriene-1-one derivatives and pharmaceutical preparations containing them
AU646519B2 (en) 1990-10-10 1994-02-24 Schering Corporation Pyridine and pyridine N-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and methods of use thereof
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5807858A (en) 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
FR2696744B1 (fr) 1992-10-12 1994-12-30 Logeais Labor Jacques Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
HU221726B1 (hu) 1993-07-30 2002-12-28 Ardent Pharmaceuticals Inc. Piperazinszármazékok, e vegyületeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
JP3352184B2 (ja) 1993-11-12 2002-12-03 株式会社アズウェル ピペラジン不飽和脂肪酸誘導体
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
ATE306472T1 (de) 1997-12-24 2005-10-15 Ortho Mcneil Pharm Inc (4)-(aryl(piperidin-4-yl) aminobenzamidderivate die an delta-opioid rezeptor binden
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904674D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904675D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001209D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101766D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101765D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
DE60230869D1 (de) * 2001-05-18 2009-03-05 Astrazeneca Ab 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
SE0103313D0 (sv) 2001-10-03 2001-10-03 Astrazeneca Ab Novel compounds
WO2003037342A1 (en) * 2001-10-29 2003-05-08 Ardent Pharmaceuticals, Inc. Method of treating depression with delta receptor agonist compounds
US8476280B2 (en) 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0300105D0 (sv) 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0400027D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
HRP20120343T1 (hr) 2004-08-02 2012-05-31 Astrazeneca Ab Derivati diarilmetil piperazina, njihovi pripravci i njihova uporaba
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
CN101128447A (zh) 2005-02-28 2008-02-20 阿斯利康(瑞典)有限公司 二芳基甲基哌嗪衍生物，其制备及其用途
JP2011520956A (ja) 2008-05-20 2011-07-21 アストラゼネカ・アクチエボラーグ 不安大うつ病性障害を処置する方法

Also Published As

Publication number Publication date
JP2005508293A (ja) 2005-03-31
EE200300545A (et) 2004-02-16
AR035974A1 (es) 2004-07-28
SI1395567T1 (sl) 2009-04-30
CY1108913T1 (el) 2014-07-02
IS7032A (is) 2003-11-13
DE60230869D1 (de) 2009-03-05
RU2297412C2 (ru) 2007-04-20
NZ539828A (en) 2007-01-26
KR20080106586A (ko) 2008-12-08
BR0209678A (pt) 2004-09-14
NO326632B1 (no) 2009-01-26
MY140070A (en) 2009-11-30
NZ529401A (en) 2005-09-30
WO2002094794A1 (en) 2002-11-28
EP1395567A1 (en) 2004-03-10
WO2002094794A8 (en) 2004-04-22
DK1395567T3 (da) 2009-04-06
SK13982003A3 (sk) 2004-04-06
CZ20033092A3 (cs) 2004-08-18
ES2319876T3 (es) 2009-05-14
KR100915263B1 (ko) 2009-09-03
US20040147526A1 (en) 2004-07-29
EP2042495A1 (en) 2009-04-01
PL367142A1 (en) 2005-02-21
PT1395567E (pt) 2009-03-26
US8022074B2 (en) 2011-09-20
JP2010132670A (ja) 2010-06-17
RU2003131964A (ru) 2005-05-10
ATE420866T1 (de) 2009-01-15
CA2446326A1 (en) 2002-11-28
BG108333A (bg) 2004-12-30
EE05243B1 (et) 2009-12-15
SK287555B6 (sk) 2011-01-04
IL158631A (en) 2010-12-30
HUP0401086A2 (hu) 2004-08-30
AU2002305994B2 (en) 2008-06-26
EP1395567B1 (en) 2009-01-14
MXPA03010445A (es) 2004-03-09
US20070270435A1 (en) 2007-11-22
HK1061237A1 (en) 2004-09-10
CA2446326C (en) 2010-12-07
IS2625B (is) 2010-05-15
US7229994B2 (en) 2007-06-12
JP4549024B2 (ja) 2010-09-22
HUP0401086A3 (en) 2011-07-28
JP5028500B2 (ja) 2012-09-19
US20110039858A1 (en) 2011-02-17
KR100885100B1 (ko) 2009-02-20
US7915413B2 (en) 2011-03-29
CN1527820A (zh) 2004-09-08
KR20040000471A (ko) 2004-01-03
CO5540309A2 (es) 2005-07-29
CN1269805C (zh) 2006-08-16
NO20035120D0 (no) 2003-11-17

Similar Documents

Publication Publication Date Title
IL158631A0 (en) 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158704A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL368804A1 (en) 4(piperidin-4-yliden-(3-carbamoylphenyl)methyl] benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders
PL376894A1 (pl) Pochodne 4-(fenylopiperazynylometylo) benzamidu i ich zastosowanie do leczenia bólu lub zaburzeń żołądkowo-jelitowych
IL158703A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL376895A1 (pl) Pochodne 4-(fenylopiperazynylometylo) benzamidu i ich zastosowanie do leczenia bólu lub zaburzeń żołądkowo-jelitowych
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2003278664A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
IL158695A0 (en) 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158628A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158630A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158629A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158700A0 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1061248A (en) 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1061032A (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1061027A (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1061028A (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
HK1061240A (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1061239A (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1061236A (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1061247A (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1079515A (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
HK1079516A (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders